- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Leqembi starts to deliver for Eisai and Biogen | ||
| Fr | Bayer reveals data behind asundexian's stroke win | ||
| Fr | White House's TrumpRx platform has arrived | ||
| Do | Hims & Hers copies Novo Nordisk's new Wegovy pill | ||
| Do | Flagship's AI-focused Generate Biomedicines files IPO | ||
| Do | Amgen baulks at FDA request to withdraw Tavneos | ||
| Do | Grail multi-cancer test taps into Hims & Hers network | ||
| Do | Abbott's wireless heart failure sensor cleared for NHS use | ||
| Do | Eikon, Veradermics close IPOs, as Salspera joins queue | ||
| Mi | Lilly says 2026 looks good, as sales rocket in Q4 | ||
| Mi | GSK delivers in new CEO Miels' first financial update | ||
| Mi | Novo Nordisk slumps on tougher 2026 financial outlook | ||
| Mi | Patent losses hit Novartis hard, but CEO has a plan | ||
| Mi | Fears US drug pricing deal will weigh heavy on the NHS | ||
| Di | GSK departs Wave's AATD programme | ||
| Di | FDA knocks back AstraZeneca's self-injected lupus drug | ||
| Di | UK will cover transport costs for children with cancer | ||
| Di | Novo Nordisk's CagriSema tops Ozempic in diabetes trial | ||
| Di | GSK kicks out of Wave's AATD programme | ||
| Mo | UK body raps Sanofi for disparaging Pfizer's RSV jab | ||
| Mo | FDA knocks back Pharming's bid for wider Joenja use | ||
| Mo | Mixed data mars Sanofi's venglustat programme | ||
| Mo | Mixed data mar Sanofi's venglustat programme | ||
| Mo | FDA launches pilot programme to boost US manufacturing | ||
| Mo | UCB bags first EU approval for rare genetic disease TK2d |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.